StemCell Therapy

Addressing gaps in testing and education within precision oncology can assist in improving access to patients of color and other underserved populations.

Addressing gaps in testing and education within precision oncology can assist in improving access to patients of color and other underserved populations, said Karen Winkfield, MD, PhD, incoming executive director, Meharry-Vanderbilt Alliance.

Transcript

AJMC: In the era of precision medicine, what can oncologists do to ensure that newer therapies are the right choice for minority patients?

Dr Winkfield: Precision oncology has really come a long way, and I do think that oftentimes people think about it as just genetic testing or genomic testing. That's important, and we do know that there's a gap, even in terms of testing, for some things as simple as an oncotype for breast cancer patients. We know that Black patients are not getting the oncotype test at the same rate as other racial and ethnic groups.

So, really, just making sure that there's access is one thing that can be important. Whether it be partnering with some of the testing facilities to make sure that there is opportunity for individuals who may be underinsured or uninsured to gain access to some of these precision oncology tests, that would be wonderful.

The other thing is making sure people understand, again, community engagement. I'm going to keep coming back to that, because patients need to understand the importance of it and know that they're not being a guinea pig, etc, but that we want to make sure that their treatment is personalized. The personalization is not just to them as an individual, but also to their tumor and what their tumor might be doing. So, that communication is important as well.

So, sometimes it may require a second biopsy. So, you can imagine, if a person has gone through therapy and then their tumor is not responding, and you say, "Oh, we need to get some more tissue," there can be some misunderstandings about that. So, really being open with your patients about the rationale and the reason for getting additional tissue, but, again, making sure that patients don't have very high out-of-pocket cost is one of the things that I think will go a long way to improving access to patients of color and other underserved populations to precision oncology.

Read more:
Dr Karen Winkfield on Improving Minority Access, Education for Precision Oncology - AJMC.com Managed Markets Network

BINYAMINA, Israel, Oct. 5, 2020 /PRNewswire/ -- OncoHost, a global leader in host response profiling for improved personalized cancer therapy, announced today that Professor Yuval Shaked, co-founder and Chief Scientific Advisor at OncoHost, and Professor of Cell Biology and Cancer Science at the Technion Israel Institute of Technology, will deliver a presentation titled A Proteomics-Based Platform for Predicting Response to Immunotherapy and Personalizing Treatment Plans at the MAP 2020 Virtual Congress - ESMOthis Friday, October 9th at 17:20 PM CEST.

The presentation will show how through the analysis of host response profiles (i.e. the patient's reaction), oncologists may be able to harness this information to better predict clinical outcomes and suggest the ideal combination treatment with immunotherapy.

"Despite major clinical success, immunotherapy treatments have demonstrated efficacy in only a small proportion of patients with non-small cell lung cancer (NSCLC)," said Prof. Yuval Shaked. "OncoHost's studies have indicated that individual host response to anti-cancer treatment can generate pro-tumorigenic activities and support tumor re-growth and spread. It is therefore vital to analyze and earlier predict host response to treatment in order to improve outcomes and reduce unnecessary side effects experienced by so many patients."

Using machine learning (ML)-based analysis and algorithms to identify highly predictive cohort-based proteomic signatures in patients, personalized response prediction can be used to improve precision medicine in oncology. Personalized treatment plans can then be created through information based on cohort-based statistical analysis, personalized adaption and finally, translation to clinically relevant targets.

Prof. Shaked's presentation willinclude a real-life case study on whom a Host Response profile analysis was performed, and will be followed by a live Q&A.

MAP is the leading congress in precision medicine in oncology in Europe, established by key opinion leaders in the field. The name of the Congress was recently changed into Molecular Analysis for Precision Oncology to better reflect its aims of focusing on science, translational research, education and collaboration. This year's event will be held virtually on October 9-10.

About OncoHost

OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients' unique response to therapy and overcome one of the major obstacles in clinical oncology today resistance to therapy. OncoHost's Host Response Profiling platform (PROphet) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet also identifies potential drug targets, advancing the development of novel therapeutic strategies as well as rationally based combination therapies.

For more information, visithttp://www.oncohost.com

Follow OncoHost onLinkedIn

OncoHost Media Contact: Ellie HansonFinn Partners [emailprotected]+1 929-222-8006

SOURCE OncoHost

https://oncohost.com/

Read the original here:
OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress - ESMO - PRNewswire

OncoHost, announced on 5th October that Professor Yuval Shaked, co-founder and Chief Scientific Advisor at OncoHost, and Professor of Cell Biology and Cancer Science at the Technion Israel Institute of Technology, will deliver a presentation titled A Proteomics-Based Platform for Predicting Response to Immunotherapy and Personalizing Treatment Plans at the MAP 2020 Virtual Congress - ESMO this Friday, October 9th at 17:20 PM CEST.

The presentation will show how through the analysis of host response profiles (i.e. the patients reaction), oncologists may be able to harness this information to better predict clinical outcomes and suggest the ideal combination treatment with immunotherapy.

Despite major clinical success, immunotherapy treatments have demonstrated efficacy in only a small proportion of patients with non-small cell lung cancer (NSCLC), said Prof. Yuval Shaked. OncoHosts studies have indicated that individual host response to anti-cancer treatment can generate pro-tumorigenic activities and support tumor re-growth and spread. It is therefore vital to analyze and earlier predict host response to treatment in order to improve outcomes and reduce unnecessary side effects experienced by so many patients.

Using machine learning (ML)-based analysis and algorithms to identify highly predictive cohort-based proteomic signatures in patients, personalized response prediction can be used to improve precision medicine in oncology. Personalized treatment plans can then be created through information based on cohort-based statistical analysis, personalized adaption and finally, translation to clinically relevant targets.

Prof. Shakeds presentation will include a real-life case study on whom a Host Response profile analysis was performed, and will be followed by a live Q&A.

MAP is the leading congress in precision medicine in oncology in Europe, established by key opinion leaders in the field. The name of the Congress was recently changed into Molecular Analysis for Precision Oncology to better reflect its aims of focusing on science, translational research, education and collaboration. This years event will be held virtually on October 9-10.

Excerpt from:
OncoHost Data on Host Immunotherapy Response to be Presented This Week - Technology Networks

While ride-sharing services like Grab, Uber, and Gojek have become a pervasive part of life, many countries in the Asia Pacific region are still unconvinced when it comes to micro-mobilities such as bike and scooter sharing. While the convenience offered by these is great, especially in this Covid-19 era when people may remain wary of crowding in buses and metro trains, there is a need for in-depth knowledge of these new transportation options to help guide policy and regulation.

A group of scientists in the Senseable City Lab at MIT and the Future Urban Mobility (FM) Interdisciplinary Research Group at the Singapore-MIT Alliance for Research and Technology (SMART), MITs research enterprise in Singapore, set out to better understand the phenomenon and inform policy-making through a comparative analysis of bike-sharing and scooter-sharing activities in Singapore.

The researchers shared their findings in a paper titled Understanding spatio-temporal heterogeneity of bike-sharing and scooter-sharing mobility published in the journal Computers, Environment and Urban Systems. The study is based on real usage records containing location and time of departures and arrivals in two distinct areas in Singapore.

We constructed historical trajectories of the bike-sharing and scooter-sharing trips and compared usage patterns of the two systems at the Marina Bay area and the NUS campus, says Rui Zhu, a postdoc at SMART FM. Our results showed increased sharing frequency and decreased fleet size for scooter-sharing, suggesting that it performs better than bike-sharing.

More specifically, the sharing frequency was increased from less than one time per day for bike-sharing to more than three times per day for scooter-sharing, but the researchers believe that can be improved even further to create a more profitable service.

The study also found that shared scooters in Marina Bay were frequently left away from their designated parking spaces or charging stations, indicating costly and labor-intensive maintenance since employees need to collect and transport scooters between stations continuously. However, the statistics also showed that over 28 percent and 26 percent of trips departed from and arrived at non-stations respectively, suggesting that users actually utilized most of the inappropriately returned scooters.

In addition, the study revealed quantitative changes in trips over time, distances, and duration, and the influence of weather on the demand of micro-mobilities.

In Singapore and a few other cities, dockless bike-sharing systems rose and fell in just one year, followed by an explosion of docking scooter-sharing systems. But we didnt have the necessary insights for appropriate business and policy decisions, Zhu explains. Our study goes deeper into the problems and possibilities of micro-mobility sharing and suggests how these services can be improved.

To facilitate a sustainable scooter-sharing service, the researchers suggest optimizing the fleet size of stations and their locations, regulating returning behaviors more strictly, enabling scooters to have autonomous repositioning functionality, and increasing the useful battery life of scooters.

To increase battery life, they suggest installing a photovoltaic module on scooters for solar charging during trips and parking time or equipping conventional dock-based stations with grid charging or solar charging platforms, allowing for an environmentally friendly solution that will be able to reduce carbon footprints.

While the business model and user behavior greatly impact the success of mobility-sharing services, government policy also plays a significant role. Supportive policies or regulations on controlling fleet sizes and limiting usage to discrete areas are huge drivers for the sustainable development of the new transportation modes. With this study, SMARTs researchers hope to fill existing gaps in knowledge about micro-mobility sharing to help inform policy decisions.

SMART was established by MIT in partnership with the National Research Foundation of Singapore (NRF) in 2007. SMART is the first entity in the Campus for Research Excellence and Technological Enterprise (CREATE) developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, performing cutting-edge research in areas of interest to both. SMART currently comprises an Innovation Center and six Interdisciplinary Research Groups: Future Urban Mobility, Antimicrobial Resistance, BioSystems and Micromechanics, Critical Analytics for Manufacturing Personalized-Medicine, Disruptive and Sustainable Technologies for Agricultural Precision, and Low Energy Electronic Systems.

The Future Urban Mobility group harnesses new technological and institutional innovations to create the next generation of urban mobility systems to increase accessibility, equity, safety, and environmental performance for the citizens and businesses of Singapore and other metropolitan areas, worldwide.

SMART research is supported by the NRF and situated in CREATE.

See more here:
Comparing the benefits of scooter-sharing vs. bike-sharing - MIT News

The treatment given to POTUS is the abstraction we all desire personalized medicine. Just the right treatment, at the right time, in the right way. Of course, physicians' day-to-day dilemma is translating guidelines and treatments tested upon populations into efficacious care for the individual sitting across from your desk. And that dilemma is compounded when you deal with VIPs

It is not March; when the virus didn't respond to the treatments that had always worked so well for influenza - we threw everything we had at the problem. While we have made significant progress in treating COVID-19, I do not believe we have a set-in-place protocol for what to do when. There is a broad outline of medications that may reduce symptoms, improve outcomes, and reduce the length of stay lots of ingredients, lots of chefs, but no classic recipe.

All of the medications that the President has been publically acknowledged as receiving reduce symptoms.

Ethical medicine, "shared decision making" between patient and physician requires that I provide you with options, state which I feel is the best approach and why, and together we choose a path forward. The President's care, as with most VIPs, involves lots of chefs. Many chefs with nuanced opinions that by consensus, majority vote, or eminence eventually become a treatment plan. [1] One of the difficulties in treating VIPs, in general, is that in many instances, they believe their eminence extends to being a chef too. They can be very "hands-on" when it comes to choosing treatments and what to pursue.

The patient applies any factors they feel are relevant in that calculus. I think it is apparent that the President has included a political component to his choices. This is not the time to appear weak physically or emotionally. His motorcade to his supporters is an example of powerful eminence in action. As a rule, hospitals don't allow you to leave for a few hours and return; in many cases, chronic smokers with significant addiction to nicotine are not allowed to go outside for a cigarette.

Of course, it takes two to make a medical decision; you still need a physician. Can we reasonably believe that the phrase "an abundance of caution" has not impacted their clinical judgment? Additionally, by my count, the President has had at least three physicians, including his private one, since taking office. The idea that he has a deep enough long-term relationship with any of them that would allow for considered choice is silly; in that way, the President echoes some of our behavior, honoring primary care in word but not deed.

Words matter and their meaningvariessignificantly from one context to another. Consider Chris Christie, who "checked himself in" to a hospital over the weekend. Hospitals are not hotels; you don't check-in; you are admitted to the hospital by an attending physician who has determined you have met the admission criteria. You only would describe admission to the hospital as checking-in to make it seem more an optional vacation choice, less a medical need.

Or the announcement that the President may go home to continue care, you shouldn't take that to mean he is like a typical COVID-19 patient being discharged from the hospital; unless, of course, that patient has a fully equipped Emergency Department and physicians standing by in their home.

It is a fool's errand to guess at the President's clinical status based on his receiving treatment. Whether he received supplemental oxygen doesn't necessarily mean he was more ill or that the doctors acted out of an abundance of caution. What is supplemental oxygen, 2 liters/min or 8, nasal prongs, or face mask? We cannot tell.

He is receiving personalized care, not care from some guidelines that haven't even been formulated. His treatment, like ours, is or should be, is personalized to his needs. It may very well be that his perception of his non-medical needs overrides his physicians' medical judgment, but that is a problem all doctors and patients face.

[1] One of the problems for VIPS is that, in some cases, "too many cooks do spoil the soup." If you don't believe me take a look at themedical decisionssurrounding President Garfield, "At least a dozen medical experts probed the president's wound, often with unsterilized metal instruments or bare hands, as was common at the time." Or look at thecare of the Shah of Iran, whose cancer was treated by the world's best cardiac surgeon, with a very poor outcome.

Read more:
Managing the President's COVID-19 - American Council on Science and Health

Oct. 6, 2020 05:30 UTC

STRASBOURG, France & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- Regulatory News:

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader in IT and network technologies and BostonGene Corporation (BostonGene), a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a strategic collaboration for two ongoing Phase 1 clinical trials of TG4050, an individualized therapeutic vaccine for ovarian and head & neck cancers based on Transgenes proprietary myvac platform and NECs AI-driven Neoantigen Prediction System in Europe and the United States.

Transgenes myvac platform brings together a series of highly innovative technologies, such as viral genome engineering, to achieve high-speed modular manufacturing of bespoke immunotherapies.

TG4050 is an individualized cancer vaccine based on the myvac platform; it is based on an optimized viral platform for cancer vaccination and integrates NECs artificial intelligence capabilities. This therapeutic vaccine aims at stimulating the immune system of patients to induce a T-cell response against tumor-specific antigenic alterations, called neoantigens. These neoantigens are derived from genomic mutations and selected using NECs Neoantigen Prediction System, an advanced AI technology that has already been applied in the field of oncology. TG4050 has been designed to target up to 30 patient-specific neoantigens. Transgene is sponsoring two Phase 1 trials that are expected to deliver a first proof of concept of this virus-based individualized approach.

As part of the collaboration, BostonGene will conduct genomic and transcriptomic analyses of primary patient tumors collected from patients enrolled in these two clinical trials to identify predictors of response to TG4050 and the cancer cell-intrinsic and -extrinsic factors that may mediate each patients response to the vaccine. BostonGenes platform integrates the genomic and transcriptomic analyses to simultaneously assess the activity of the tumor and the microenvironment through the identification of significant somatic alterations, evaluation of gene expression, estimation of tumor heterogeneity and classification of the microenvironment.

BostonGene generates a Tumor Portrait Report, involving the data-driven, visually appealing and self-explanatory tumor schematics elegantly depicting tumor activity, tumor cellular composition, and functionality of the immune-microenvironment and other tumor-associated processes. The comprehensive report will provide insights into the individual oncogenic state and immunogenicity of the patients tumor.

BostonGenes unique solution and deep expertise in Next Generation Sequencing (NGS) analysis provide us with the detailed profiles of a tumor and its micro-environment. These Tumor Portrait Reports will help us look at our patient data in light of the current published evidence and could help us accelerate the development of TG4050, said ric Qumneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene. This novel way of analyzing patient data is part of an ambitious translational program that supports the development of our myvac platform. By integrating these types of approaches into our studies, we seek to build an integrated framework for the use of viral-based immunotherapeutics.

NEC looks forward to strengthening its collaboration with BostonGene through these trials of TG4050. BostonGenes advanced analysis of NGS among cancer patients provides excellent profiling that we believe will add important insight into the understanding of each patients tumor environment and how it reflects on the clinical outcomes of our treatment, said Osamu Fujikawa, Senior Vice President at NEC Corporation.

BostonGene is proud to support Transgene and NEC during these critical Phase 1 clinical trials, said Nathan Fowler, MD, Chief Medical Officer at BostonGene. This collaboration represents our ongoing commitment to improve immunotherapy options and transform personalization of treatment for cancer patients.

About TG4050 TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgenes myvac technology and powered by NECs longstanding artificial intelligence (AI) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NECs Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic sequences.

TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed for each patient and can be produced in a very short time frame.

This best-in-class candidate is being evaluated in two Phase 1 clinical trials for patients with ovarian cancers (NCT03839524) and HPV-negative head and neck cancers (NCT04183166).

About myvac myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac-derived products are designed to stimulate the patients immune system, recognize and destroy tumors using the patients own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded Investment for the Future funding from Bpifrance for the development of its platform myvac. TG4050 is the first myvac-derived product being evaluated in clinical trials.

About NEC's Neoantigen Prediction System NEC's neoantigen prediction utilizes its proprietary artificial intelligence (AI), such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets. NEC comprehensively evaluates the candidate neoantigens with a primary focus placed on its in-house major histocompatibility complex (MHC) binding affinity prediction trained on public and proprietary datasets. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.

About Transgene Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgenes programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Companys clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO platform).

With Transgenes myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO collaboration with AstraZeneca.

Additional information about Transgene is available at: http://www.transgene.fr.

Follow us on Twitter: @TransgeneSA

About NEC Corporation NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of Orchestrating a brighter world. NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.

About BostonGene Corporation BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGenes unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGenes mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

Transgene disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Companys activities, perspectives, financial situation, results, regulatory authorities agreement with development phases, and development. The Companys ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Companys actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (Facteurs de Risque) section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgenes website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005838/en/

Read the original:
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers -...

A new modeling tool may be able to help doctors assess which treatments are best for individual patients with colorectal cancer. The artificial intelligence program analyzes a patient's disease details -- such as the stage of cancer and other chronic conditions -- and compares those details to other colorectal cancer cases to predict the patient's chance of surviving past 10 years.

"Predicting survival of cancer patients as a means to help determine treatments is not new," said Jean Emmanuel Bibault, MD, PhD, a radiation oncologist who led the study. "But current standard techniques are not very accurate, and we're hoping that by using AI we can bring more precise information to doctors as they make crucial decisions about care."

Predicting a cancer patient's survival time lends valuable insight into the best course of treatment for both the long and short term, helping to determine what is likely most suitable.

The online tool works by assessing 32 details about an individual patient, such as age, the stage of the cancer, exercise habits, cholesterol levels, history of chronic disease and much more.

After these details are input into the tool, the algorithm predicts how long that person might live and reports a number in years. The tool also provides context, citing the top reasons for its calculation, such as the stage of the cancer, the patient's age at diagnosis, or how the patient was initially treated.

"From a physician's point of view, we want to know how well our patients are going to do from the get-go. We're looking at two main things: how to choose the right therapy, and if we can alter their destiny," said Daniel Chang, MD, professor of radiation oncology, who is an author of the study.

"Some folks have a bit of a nihilistic point of view," he continued, "that survival is determined by the genetics of your cancer and of your body. But the question is: Can anything we, as doctors, do change that outcome if we do it sooner or do it differently from the start? That's where I see a lot of value for this research."

An abstract on the research appeared online inGut.

Bibault, Chang and professor of radiation oncology, Lei Xing, PhD, devised the algorithm powering the prediction tool with data made available through the National Institutes of Health, from thousands of de-identified patients who have or had colorectal cancer at various stages and are of varying ages.

The team trained the algorithm to track survival of thousands of patients, in conjunction with the details of their disease and some details about their course of treatment. In this way, the algorithm uses the outcomes and survival rates of past cohorts to calculate the chance of survival for future patients.

So far, the tool has been about 90% accurate in predictions it made on 472 patient cases that were not used to train the tool. The tool has not been used in a clinical setting.

"The treatments that we have nowadays are becoming more and more specialized, targeted, in many cases intensified. And the reality is that not everybody is going to benefit from new treatments, therapies or technologies in the same way," said Chang.

"This algorithm could allow us a better shot at personalized medicine, and enhance our ability to tailor the treatments to be as appropriate as possible," he added.

Although patients could use the tool on their own, Bibault said the ideal application would be for doctors and patients to use the tool together. That way, doctors would be able to contextualize the result and answer any patient questions.

The team's goal is to enhance the algorithm's accuracy and to find other applications for it.

"We have laid the foundation for this model," said Bibault, "and we're hopeful it can apply to other cancer types as well."

Photo by National Cancer Institute

Read more:
AI tool created to guide colorectal cancer care with more precision - Scope

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the clinical mass spectrometry market and it is poised to grow by USD 1.70 billion during 2020-2024, progressing at a CAGR of almost 6% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR44340

This Report Addresses:

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions-

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Agilent Technologies Inc., Bruker Corp., Danaher Corp., Hitachi Ltd., JEOL Ltd., Kore Technology Ltd., PerkinElmer Inc., Shimadzu Corp., Thermo Fisher Scientific Inc., and Waters Corp. are some of the major market participants. The rise in geriactric population will offer immense growth opportunities. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Clinical Mass Spectrometry Market 2020-2024: Segmentation

Clinical Mass Spectrometry Market is segmented as below:

Clinical Mass Spectrometry Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The clinical mass spectrometry market report covers the following areas:

This study identifies increasing demand for clinical mass spectrometry in personalized medicine as one of the prime reasons driving the clinical mass spectrometry market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Clinical Mass Spectrometry Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by End-user

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

The rest is here:
Clinical Mass Spectrometry Market by End-User (Healthcare Facilities and Pharma and Biotech Companies and Research Labs and Institutes) and Geography...

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology (SMART), MITs research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation (NRF) Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries. The grants are part of the NRFs initiative to bring together researchers from Campus for Research Excellence And Technological Enterprise (CREATE) partner institutions, in order to achieve greater impact from collaborative research efforts.

SMART CAMP was formed in 2019 to focus on ways to produce living cells as medicine delivered to humans to treat a range of illnesses and medical conditions, including tissue degenerative diseases, cancer, and autoimmune disorders.

Singapores well-established biopharmaceutical ecosystem brings with it a thriving research ecosystem that is supported by skilled talents and strong manufacturing capabilities. We are excited to collaborate with our partners in Singapore, bringing together an interdisciplinary group of experts from MIT and Singapore, for new research areas at SMART. In addition to our existing research on our three flagship projects, we hope to develop breakthroughs in manufacturing other cell therapy platforms that will enable better medical treatments and outcomes for society, says Krystyn Van Vliet, co-lead principal investigator at SMART CAMP, professor of materials science and engineering, and associate provost at MIT.

Understanding glaucoma progression for better-targeted treatments

Hosted by SMART CAMP, the first research project, Retinal Analytics via Machine learning aiding Physics (RAMP), brings together an interdisciplinary group of ophthalmologists, data scientists, and optical scientists from SMART, Singapore Eye Research Institute (SERI), Agency for Science, Technology and Research (A*STAR), Duke-NUS Medical School, MIT, and National University of Singapore (NUS). The team will seek to establish first principles-founded and statistically confident models of glaucoma progression in patients. Through retinal biomechanics, the models will enable rapid and reliable forecast of the rate and trajectory of glaucoma progression, leading to better-targeted treatments.

Glaucoma, an eye condition often caused by stress-induced damage over time at the optic nerve head, accounts for 5.1 million of the estimated 38 million blind in the world and 40 percent of blindness in Singapore. Currently, health practitioners face challenges forecasting glaucoma progression and its treatment strategies due to the lack of research and technology that accurately establish the relationship between its properties, such as the elasticity of the retina and optic nerve heads, blood flow, intraocular pressure and, ultimately, damage to the optic nerve head.

The research is co-led by George Barbastathis, principal investigator at SMART CAMP and professor of mechanical engineering at MIT, and Aung Tin, executive director at SERI and professor at the Department of Ophthalmology at NUS. The team includes CAMP principal investigators Nicholas Fang, also a professor of mechanical engineering at MIT; Lisa Tucker-Kellogg, assistant professor with the Cancer and Stem Biology program at Duke-NUS; and Hanry Yu, professor of physiology with the Yong Loo Lin School of Medicine, NUS and CAMPs co-lead principal investigator.

We look forward to leveraging the ideas fostered in SMART CAMP to build data analytics and optical imaging capabilities for this pressing medical challenge of glaucoma prediction, says Barbastathis.

Cell transplantation to treat irreparable spinal cord injury

Engineering Scaffold-Mediated Neural Cell Therapy for Spinal Cord Injury Treatment (ScaNCellS), the second research project, gathers an interdisciplinary group of engineers, cell biologists, and clinician scientists from SMART, Nanyang Technological University (NTU), NUS, IMCB A*STAR, A*STAR, French National Centre for Scientific Research (CNRS), the University of Cambridge, and MIT. The team will seek to design a combined scaffold and neural cell implantation therapy for spinal cord injury treatment that is safe, efficacious, and reproducible, paving the way forward for similar neural cell therapies for other neurological disorders. The project, an intersection of engineering and health, will achieve its goals through an enhanced biological understanding of the regeneration process of nerve tissue and optimized engineering methods to prepare cells and biomaterials for treatment.

Spinal cord injury (SCI), affecting between 250,00 and 500,000 people yearly, is expected to incur higher societal costs as compared to other common conditions such as dementia, multiple sclerosis, and cerebral palsy. SCI can lead to temporary or permanent changes in spinal cord function, including numbness or paralysis. Currently, even with the best possible treatment, the injury generally results in some incurable impairment.

The research is co-led by Chew Sing Yian, principal investigator at SMART CAMP and associate professor of the School of Chemical and Biomedical Engineering and Lee Kong Chian School of Medicine at NTU, and Laurent David, professor at University of Lyon (France) and leader of the Polymers for Life Sciences group at CNRS Polymer Engineering Laboratory. The team includes CAMP principal investigators Ai Ye from Singapore University of Technology and Design; Jongyoon Han and Zhao Xuanhe, both professors at MIT; as well as Shi-Yan Ng and Jonathan Loh from Institute of Molecular and Cell Biology, A*STAR.

Chew says, Our earlier SMART and NTU scientific collaborations on progenitor cells in the central nervous system are now being extended to cell therapy translation. This helps us address SCI in a new way, and connect to the methods of quality analysis for cells developed in SMART CAMP.

Cell therapy, one of the fastest-growing areas of research, will provide patients with access to more options that will prevent and treat illnesses, some of which are currently incurable. Glaucoma and spinal cord injuries affect many. Our research will seek to plug current gaps and deliver valuable impact to cell therapy research and medical treatments for both conditions. With a good foundation to work on, we will be able to pave the way for future exciting research for further breakthroughs that will benefit the health-care industry and society, says Hanry Yu, co-lead principal investigator at SMART CAMP, professor of physiology with the Yong Loo Lin School of Medicine, NUS, and group leader of the Institute of Bioengineering and Nanotechnology at A*STAR.

The grants for both projects will commence on Oct. 1, with RAMP expected to run until Sept. 30, 2022, and ScaNCellS expected to run until Sept. 30, 2023.

SMART was. established by the MIT in partnership with the NRF in 2007. SMART is the first entity in the CREATE developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, undertaking cutting-edge research projects in areas of interest to both Singapore and MIT. SMART currently comprises an Innovation Centre and five interdisciplinary research groups (IRGs): Antimicrobial Resistance, CAMP, Disruptive and Sustainable Technologies for Agricultural Precision, Future Urban Mobility, and Low Energy Electronic Systems.

CAMP is a SMART IRG launched in June 2019. It focuses on better ways to produce living cells as medicine, or cellular therapies, to provide more patients access to promising and approved therapies. The investigators at CAMP address two key bottlenecks facing the production of a range of potential cell therapies: critical quality attributes (CQA) and process analytic technologies (PAT). Leveraging deep collaborations within Singapore and MIT in the United States, CAMP invents and demonstrates CQA/PAT capabilities from stem to immune cells. Its work addresses ailments ranging from cancer to tissue degeneration, targeting adherent and suspended cells, with and without genetic engineering.

CAMP is the R&D core of a comprehensive national effort on cell therapy manufacturing in Singapore.

See the original post:
SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapy - MIT News

When people find out Azizi Seixas studies sleep, they sometimes ask him about their dreams. Thats not really his fieldbut he does have big dreams for his own research. By using technology to combine precision medicine with population-level research, he hopes to erase disparities and bring better health to all.

Growing up in inner-city Kingston, Jamaica, I was the have-nots, Seixas says. He learned early lessons about inequality andbeing raised by seven women in a three-bedroom homeresourcefulness. Today hes carried those lessons to New York Universitys Grossman School of Medicine, where hes an assistant professor of population health and psychiatry. In his lab, Seixas explores why certain groups such as racial and ethnic minorities have higher risks of chronic illnesses, the long-term consequences of those disparities, and how people can change their behavior to improve their health.

Sleep has been a kind of lens through which Seixas looks at these questions. For example, how are disparities in peoples sleep related to heart disease risk and other health effects? And how might doctors tailor sleep advice to individuals, along with their other recommendations?

Thats important because sleep plays an integral role in our health 24/7, not just the hours were in bed. Sleep is not just the act of unconsciousness, Seixas says. Besides keeping our bodies refreshed and running, sleep is important for consolidating things weve learned, and for cleansing our brains of protein gunk thats linked to Alzheimers disease.

Yet not everyone can get as much sleep as they need. He gives the example of a single mother who works two jobs. If he tells her she needs to sleep eight or nine hours a night, Shell look at me and scoff, Seixas says. And they have, to be quite honest.

Seixas imagines working with that single mom to figure out ways to offset her lost sleep using other health recommendations. Maybe dialing up her exercise can lower her risk of certain diseases, even while she continues squeezing in just six hours a night. If exercising more isnt feasible, maybe she can adjust her diet instead. The data to make this happen might come from wearable technologies that track the moms activities and biometrics, as well as artificial intelligence and machine-learning models that predict how changes to her behaviors will affect her health.

Scientists are still learning about the intricate ways our traits, behaviors, and risks may affect each other, so this scenario is still hypothetical. But one goal of Seixass research is to be able to personalize the advice a doctor gives a patient, rather than assuming that the same guidance is right for everybody. Seixas calls his philosophy precision and personalized population health. He thinks general guidelines for the public are important, too. But to fulfill what he calls his sacrosanct role in public health, he wants to find precisely the right way to help that single mother, or anyone else, stay healthy.

How is their nightly sleep related to their daily steps?

Some of his research hints that it might be possible. In a 2018 paper, he and his colleagues used machine learning to analyze survey data from more than 280,000 people about whether theyd had a stroke, as well as their age, sex, nightly sleep, and physical activity. The analysis showed which combinations of factors put people at higher or lower risk of strokes. In a similar 2017 paper, Seixas and others calculated which combinations of activity, sleep, stress, and body mass index were linked to the lowest diabetes risk in Black and white Americans.

The more health data he can include from a diverse range of people, the better the recommendations that might emerge from it. Among many other projects to help improve these datasets, Seixas is soon launching a study with funding from Merck that will focus on people with hypertension and diabetes. Seixas and his team created an app that will give participants higher-level analyses from the Fitbits or other health trackers they already use. For example, how is their nightly sleep related to their daily steps? The app will also automatically gather health-related news and articles that might interest the user. And, critically, it will tell users about clinical trials they can enroll in. We want to appeal to the greater good of individuals, Seixas says, tapping into peoples drive for altruism and volunteering to fight chronic health conditions.

Encouraging more people to enroll in clinical trialswhich include trials of behavioral changes, not just tests of new drugscould help researchers get better data on underrepresented groups. Seixas hopes it could also help the public to see science in a positive light. Especially now, he says, where you have political figures questioning whether or not science should be the bright force that it has always been.

Seixass ideas are especially timely during COVID-19, says Girardin Jean-Louis, a professor of population health and psychiatry at NYU Langone Health, who is Seixass mentor. During the pandemic, vulnerable communities are having an especially hard time accessing healthcare. His research is poised to address how various health issues plaguing underserved communities can be addressed adequately, Jean-Louis says.

Seixas hopes the questions he and his research group at NYU are asking will someday help to transform healthcare. We have very ambitious dreams and goals, he says.

Go here to read the rest:
Big Dreams of Personalized Health - NEO.LIFE

The global Personalized Medicine market focuses on encompassing major statistical evidence for the Personalized Medicine industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Personalized Medicine study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Personalized Medicine industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Personalized Medicine market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Personalized Medicine report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Personalized Medicine market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Personalized Medicine Market report @ https://hongchunresearch.com/request-a-sample/41081

Key players in the global Personalized Medicine market covered in Chapter 4:Amgen Inc.GE HealthcareSiemens Healthcare Diagnostics Inc.Asuragen IncQiagen Inc.Becton Dickinson & Co.Agendia NVPfizer Inc.Bristol-Myers SquibbAbbott

In Chapter 11 and 13.3, on the basis of types, the Personalized Medicine market from 2015 to 2026 is primarily split into:PM DiagnosticsPM TherapeuticsPersonalized Medical CarePersonalized Nutrition & Wellness

In Chapter 12 and 13.4, on the basis of applications, the Personalized Medicine market from 2015 to 2026 covers:Diagnosis and interventionDrug development and usageCancer genomics

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

The Personalized Medicine market study further highlights the segmentation of the Personalized Medicine industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Personalized Medicine report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Personalized Medicine market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Personalized Medicine market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Personalized Medicine industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Personalized Medicine Market Report with [emailprotected]https://hongchunresearch.com/report/personalized-medicine-market-41081

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Personalized Medicine Market

Chapter Four: Players Profiles

Chapter Five: Global Personalized Medicine Market Analysis by Regions

Chapter Six: North America Personalized Medicine Market Analysis by Countries

Chapter Seven: Europe Personalized Medicine Market Analysis by Countries

Chapter Eight: Asia-Pacific Personalized Medicine Market Analysis by Countries

Chapter Nine: Middle East and Africa Personalized Medicine Market Analysis by Countries

Chapter Ten: South America Personalized Medicine Market Analysis by Countries

Chapter Eleven: Global Personalized Medicine Market Segment by Types

Chapter Twelve: Global Personalized Medicine Market Segment by Applications12.1 Global Personalized Medicine Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Personalized Medicine Sales and Market Share by Applications (2015-2020)12.1.2 Global Personalized Medicine Revenue and Market Share by Applications (2015-2020)12.2 Diagnosis and intervention Sales, Revenue and Growth Rate (2015-2020)12.3 Drug development and usage Sales, Revenue and Growth Rate (2015-2020)12.4 Cancer genomics Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Personalized Medicine Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/41081

List of tablesList of Tables and FiguresTable Global Personalized Medicine Market Size Growth Rate by Type (2020-2026)Figure Global Personalized Medicine Market Share by Type in 2019 & 2026Figure PM Diagnostics FeaturesFigure PM Therapeutics FeaturesFigure Personalized Medical Care FeaturesFigure Personalized Nutrition & Wellness FeaturesTable Global Personalized Medicine Market Size Growth by Application (2020-2026)Figure Global Personalized Medicine Market Share by Application in 2019 & 2026Figure Diagnosis and intervention DescriptionFigure Drug development and usage DescriptionFigure Cancer genomics DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Personalized Medicine Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Personalized Medicine Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Personalized MedicineFigure Production Process of Personalized MedicineFigure Manufacturing Cost Structure of Personalized MedicineFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Amgen Inc. ProfileTable Amgen Inc. Production, Value, Price, Gross Margin 2015-2020Table GE Healthcare ProfileTable GE Healthcare Production, Value, Price, Gross Margin 2015-2020Table Siemens Healthcare Diagnostics Inc. ProfileTable Siemens Healthcare Diagnostics Inc. Production, Value, Price, Gross Margin 2015-2020Table Asuragen Inc ProfileTable Asuragen Inc Production, Value, Price, Gross Margin 2015-2020Table Qiagen Inc. ProfileTable Qiagen Inc. Production, Value, Price, Gross Margin 2015-2020Table Becton Dickinson & Co. ProfileTable Becton Dickinson & Co. Production, Value, Price, Gross Margin 2015-2020Table Agendia NV ProfileTable Agendia NV Production, Value, Price, Gross Margin 2015-2020Table Pfizer Inc. ProfileTable Pfizer Inc. Production, Value, Price, Gross Margin 2015-2020Table Bristol-Myers Squibb ProfileTable Bristol-Myers Squibb Production, Value, Price, Gross Margin 2015-2020Table Abbott ProfileTable Abbott Production, Value, Price, Gross Margin 2015-2020Figure Global Personalized Medicine Sales and Growth Rate (2015-2020)Figure Global Personalized Medicine Revenue ($) and Growth (2015-2020)Table Global Personalized Medicine Sales by Regions (2015-2020)Table Global Personalized Medicine Sales Market Share by Regions (2015-2020)Table Global Personalized Medicine Revenue ($) by Regions (2015-2020)Table Global Personalized Medicine Revenue Market Share by Regions (2015-2020)Table Global Personalized Medicine Revenue Market Share by Regions in 2015Table Global Personalized Medicine Revenue Market Share by Regions in 2019Figure North America Personalized Medicine Sales and Growth Rate (2015-2020)Figure Europe Personalized Medicine Sales and Growth Rate (2015-2020)Figure Asia-Pacific Personalized Medicine Sales and Growth Rate (2015-2020)Figure Middle East and Africa Personalized Medicine Sales and Growth Rate (2015-2020)Figure South America Personalized Medicine Sales and Growth Rate (2015-2020)Figure North America Personalized Medicine Revenue ($) and Growth (2015-2020)Table North America Personalized Medicine Sales by Countries (2015-2020)Table North America Personalized Medicine Sales Market Share by Countries (2015-2020)Figure North America Personalized Medicine Sales Market Share by Countries in 2015Figure North America Personalized Medicine Sales Market Share by Countries in 2019Table North America Personalized Medicine Revenue ($) by Countries (2015-2020)Table North America Personalized Medicine Revenue Market Share by Countries (2015-2020)Figure North America Personalized Medicine Revenue Market Share by Countries in 2015Figure North America Personalized Medicine Revenue Market Share by Countries in 2019Figure United States Personalized Medicine Sales and Growth Rate (2015-2020)Figure Canada Personalized Medicine Sales and Growth Rate (2015-2020)Figure Mexico Personalized Medicine Sales and Growth (2015-2020)Figure Europe Personalized Medicine Revenue ($) Growth (2015-2020)Table Europe Personalized Medicine Sales by Countries (2015-2020)Table Europe Personalized Medicine Sales Market Share by Countries (2015-2020)Figure Europe Personalized Medicine Sales Market Share by Countries in 2015Figure Europe Personalized Medicine Sales Market Share by Countries in 2019Table Europe Personalized Medicine Revenue ($) by Countries (2015-2020)Table Europe Personalized Medicine Revenue Market Share by Countries (2015-2020)Figure Europe Personalized Medicine Revenue Market Share by Countries in 2015Figure Europe Personalized Medicine Revenue Market Share by Countries in 2019Figure Germany Personalized Medicine Sales and Growth Rate (2015-2020)Figure UK Personalized Medicine Sales and Growth Rate (2015-2020)Figure France Personalized Medicine Sales and Growth Rate (2015-2020)Figure Italy Personalized Medicine Sales and Growth Rate (2015-2020)Figure Spain Personalized Medicine Sales and Growth Rate (2015-2020)Figure Russia Personalized Medicine Sales and Growth Rate (2015-2020)Figure Asia-Pacific Personalized Medicine Revenue ($) and Growth (2015-2020)Table Asia-Pacific Personalized Medicine Sales by Countries (2015-2020)Table Asia-Pacific Personalized Medicine Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Personalized Medicine Sales Market Share by Countries in 2015Figure Asia-Pacific Personalized Medicine Sales Market Share by Countries in 2019Table Asia-Pacific Personalized Medicine Revenue ($) by Countries (2015-2020)Table Asia-Pacific Personalized Medicine Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Personalized Medicine Revenue Market Share by Countries in 2015Figure Asia-Pacific Personalized Medicine Revenue Market Share by Countries in 2019Figure China Personalized Medicine Sales and Growth Rate (2015-2020)Figure Japan Personalized Medicine Sales and Growth Rate (2015-2020)Figure South Korea Personalized Medicine Sales and Growth Rate (2015-2020)Figure Australia Personalized Medicine Sales and Growth Rate (2015-2020)Figure India Personalized Medicine Sales and Growth Rate (2015-2020)Figure Southeast Asia Personalized Medicine Sales and Growth Rate (2015-2020)Figure Middle East and Africa Personalized Medicine Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Trending Report URLs:

COVID-19 Outbreak- Global Water Filter Dispensers Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2026

Global Urology Disposable Market Size, Share, 2020 Movements by Key Findings, Covid-19 Impact Analysis, Progression Status, Revenue Expectation to 2026

Read more:
Covid-19 Impact on Personalized Medicine Market Globally Growth Analysis 2020-2026 | Business Opportunities by Evolving Technologies, Global Size...

SAN ANTONIO, Oct. 1, 2020 /PRNewswire/ --Innovative Gx Laboratories, a Texas-based molecular diagnostic company, is announcing the grand opening of its central testing laboratory in San Antonio, Texas, on Oct. 1, 2020. Innovative Gx specializes in molecular diagnosis using real-time RT PCR and DNA sequencing in many medical areas. The company is a leader in personalized medical solutions such as Respiratory Pathogens, Infectious Disease, COVID-19, and DNA-based Pharmacogenetics (PGX) testing services delivering genetic-based treatment of patient care.

Innovative Gx Laboratories was founded in 2019by a team of careermedical diagnostic scientists with a combined 30+ years of experience. Its scientific team is dedicated to providing the highest-quality clinical testing services to help people reach the best health through personalized medicine. The company offers high-accuracy testing, ship-to-home (reviewed by an independent physician) or B2B solutions, offering diagnostic kitsand rapid results (often delivered in as little as less than 24 hours) for its physicians, hospitals, and clinics it serves nationwide.

Innovative Gx Laboratories provides one of the most comprehensive molecular testing options for physicians to help them accurately diagnose and treat many diseases through its targeted pharmacogenomic (PGX) panels. At present, Innovative Gx PGX panels include medications commonly prescribed to treat cardiovascular disease, mental health, infectious disease, cancer, and adverse drug interactions, and examineover 62 genes and 200 gene variants.

Innovative GX Laboratories also specializes in molecular testing of infectious disease, identification of a large range of respiratory pathogens, and RT PCR-based COVID testing. The Innovative Gx RT PCR COVID-19 Test is considered the "gold standard" in COVID screening and has received FDA authorization for emergency use. The test's level of accuracy is much higher than antigen and antibody testing and attains 99% determination of virus present.

"Our team of scientists and physicians at Innovative Gx Laboratories work diligently to offer the most comprehensive testing panels for our hospitals, physicians, and patients," said Enrique Perez-Paris, one of the co-founders of the company. He added, "Innovative Gx is much more than a business venture. It is my legacy, allowing the team at IG, to help others by providing precise health information in an accurate and timely manner."

For more information about Innovative Gx Laboratories and details of its services, please visit or contact the company at:

Innovative Gx Laboratories5410 Fredericksburg Road, Suite A304, San Antonio, Texas 78229(866) 3PCR-DNA[emailprotected] https://innovativegx.com

Related Files

InnovativeGx Laboratories Grand Opening Press Release.docx

Related Images

logo.jpg Logo

SOURCE Innovative Gx Laboratories

Innovative GX

Read more from the original source:
Innovative Gx Laboratories Announces the Grand Opening of Its Molecular Diagnostic Laboratory in Texas - PRNewswire

The Nobel Prizes for Physics, Chemistry and Medicine are the acme of scientific achievement -- honoring great minds and life-changing discoveries. But predicting who will be summoned to Stockholm and win the accolades, which are announced next week, is easy to get wrong.

That doesn't mean that people don't try.

Some look at which scientists have won so-called predictor prizes like the Lasker Awards for medical science, others analyze the fields of study favored by the Nobel Committee and tally how many years pass before a specific field is honored.

Complicating matters is that the Nobel selection committee, according to the rules laid down by Swedish industrialist Alfred Nobel in 1895, can only honor up to three people -- something that is getting harder given the collaborative nature of much scientific research.

Pandemic medicine

Unlike the peace prize, which often raises some eyebrows, the science prizes tend to honor achievements that have withstood the test of time -- last year's prize in chemistry recognized research in the development of lithium batteries from the 1980s that included honoring the oldest winner ever. The distinctions in science are thus less likely to generate controversy.

This means that it's highly unlikely that the fast-moving scientific research into Covid-19 will be featured, although many think that a drug to treat the disease or vaccine to stop its spread is a potential future winner.

That said, Gilbert Thompson, professor emeritus of clinical lipidology at Imperial College London, thinks that the committee could honor two scientists, Max Cooper and Jacques Miller, whose discovery about the organization and function of the human immune system, in particular B cells and T cells, is underpinning vaccine research.

Eman Ghanem, membership director at Sigma Xi, a global association of around 30,000 scientists that includes some 200 Nobel prize winners, is hopeful that there will be a female Nobel Laureate in science after an all-male lineup in 2019.

Success! An email has been sent to with a link to confirm list signup.

Error! There was an error processing your request.

Citations

David Pendlebury, a senior citation analyst at Clarivate Analytics, since 2002 has made 54 correct predictions (though not usually in the right year) by analyzing how often a scientist's key papers are cited by peers. Out of some 50 million scientific papers indexed since 1970, only 5,700 (or 0.01%) have been cited 2,000 or more times, and this is the pool from which his prediction are drawn.

"We're not saying that these particular people are going to win in a particular year," Pendlebury said. "We're saying these people are Nobel class and are likely to win a Nobel prize at some point.

For the physics prize, one of three contending groups Pendlebury lists is Carlos Frenk of Durham University, Julio Navarro of University of Victoria in Canada and Simon White, former director at the Max Planck Institute for Astrophysics, for their work into galaxy formation, cosmic structure and dark matter. However, Pendlebury said a win this year is unlikely because last year's physics prize for the first discovery of planets outside our solar system, led by Princeton astrophysicist James Peebles, was from the same field.

"It's highly cited, essential work, but I think it will probably be a few years till they return to a prize in cosmology," he said. "Though they could prove me wrong."

Conservative choices

The CRISPR gene-editing technology, is often mentioned as a candidate for the chemistry prize, but Pendlebury said it was a potential minefield for a Nobel Committee that likes to play it safe.

While worthy, he said several groups of scientists have been collaborating on gene editing, making it hard to narrow it down to three names. Moreover, the technology had until recently been tied up in patent wrangles. (And that's notwithstanding the ethical concerns that have dogged the technology in the wake of Chinese scientist He Jiankui, who was jailed for creating the world's first gene-edited babies.)

"I think they are making conservative choices on the significance of the science," he said.

For medicine, Pendlebury's picks include Yusuke Nakamura, a Japanese geneticist, whose contributions in pioneering whole genome sequencing gave birth to the field of personalized medicine that has revolutionized cancer treatment; and Lebanese scientist Huda Y. Zoghbi, for her work on neurological disorders including the genetic origins of Rett syndrome, a rare genetic neurological disorder that occurs primarily in girls. She was the 2017 winner of a $3 million Breakthrough Prize in Life Sciences -- founded by Sergey Brin, Priscilla Chan and Mark Zuckerberg.

"She's a very good example of someone who's likely to get Nobel recognition because of the awards she's been getting," Pendlebury said. "It's not just the accumulation of citations. Receiving these top prizes, which are chosen and selected by your peers, you get a stronger and stronger signal of how important this work has been."

Read the original here:
Why it's so hard to guess who's going to get a Nobel Prize - The Albany Herald

Hamad Bin Khalifa University (HBKU), a member of Qatar Foundation for Education, Science, and Community Development (QF), was founded in 2010 to continue fulfilling QFs vision of unlocking human potential. HBKU is a homegrown research and graduate studies University that acts as a catalyst for positive transformation in Qatar and the region while having a global impact.

About Qatar Biomedical Research Institute:

Qatar Biomedical Research Institute (QBRI), part of Hamad Bin Khalifa University (HBKU), is a national center of excellence in biomedical research. It aims to transform healthcare through harnessing and converting the latest advances in science, medicine and technology into novel discoveries that will lead to more effective treatments and preventive strategies for human diseases such as: diabetes, cancer and neurological disorders. The institute strives toward the development of novel diagnostic and therapeutic strategies to facilitate early diagnosis, treatment and management of these devastating diseases with the purpose of improving personalized medicine and healthcare. QBRI has recently occupied state-of-the-art life sciences laboratories in a newly established research campus.

Job Purpose:

To lead and develop a team of scientists and researchers leading to QBRI's growth and address developmental healthcare needs of Qatar. Conceive and establish competitive research programs including conducting translational research.

Key Result Areas:

Operating Environment, Framework & Boundaries:

Communications and Working Relationships:

Problem Solving & Complexity:

Decision-Making Authority & Responsibility:

Minimum Knowledge, Skills & Experience:

Additional Requirements

How to apply

Please submit your completed application (CV, cover letter and the names of three references with their full contact information) via the following link: Click here to apply

Hamad Bin Khalifa University, being an equal opportunity educator and employer, is committed to maintaining culturally and academically diverse staff of the highest caliber.

Read more:
Principal Investigator job with HAMAD BIN KHALIFA UNIVERSITY | 227841 - Times Higher Education (THE)

New York, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Stepper Motor Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Technology, and End user, and Country" - https://www.reportlinker.com/p05974341/?utm_source=GNW Additionally, the 3D printing technology offers a huge opportunity for medical companies in empowering a rapid production of medical implants, as well as transforming the way of planning procedures by surgeons and doctors.

Moreover, 3D-printed anatomical models are becoming essential and useful tools in the current practice of precision medicine as well as for personalized treatments.Also, additive manufacturing for the healthcare industry is still an ongoing process; however, it has already been applied in several different techniques in the medical field.

These developments in the medical field have increased the applications of stepper motors, thus, supporting the growth of stepper motor market.Based on type, the stepper motor market is further segmented into integrated lead screw stepper motor, rotary stepper motor, and fully-enclosed stepper drives.The rotary stepper motor segment held the largest share of the stepper motor market in 2019.

Rotary stepper motors are brushless and synchronous electric motors, which split a full rotation of the motor into number of equal steps.They act as synchronous AC motors comprising several poles, which are mounted on both rotor and stator.

These motors are used in a wide range of systems in an industrial setup, such as multi-axis machines, CNC machines, rotation stages, high-speed pick and place equipment, constantly driving linear actuators, linear stages, lead screws or ball screws, and mirror mounts.Several governments in APAC are taking possible steps to reduce the effects of COVID19 by announcing lockdown, which is impacting the revenue generated by the market.Although, China is one of the leading manufacturing sectors in the region, it is the most affected country in APAC due to COVID-19.

However, China has been able to minimize the spread of COVID-19, and the industries are back to normal run.Several players in the country have witnessed decline in market trends over the past three months.

Further, India, Japan, South Korea, and Taiwan are still combating the virus, and are exercising lockdown, which is hampering the growth of stepper motor market.The overall APAC stepper motor market size has been derived using primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the stepper motor market.

The process also serves the purpose of obtaining an overview and forecast for the APAC stepper motor market with respect to all the segments pertaining to the region.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic.

The participants who take part in such a process include industry experts such as VPs, business development managers, stepper motor market intelligence managers, and national sales managers along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the APAC stepper motor market. FAULHABER Group; Oriental Motor USA Corp.; SANYO DENKI CO., LTD; Nidec Corporation; Nippon Pulse Motor Co. Ltd.; ABB Ltd.; Schneider Electric SE; National Instruments Corporation; and Delta Electronic are among a few players operating in the APAC stepper motor market.Read the full report: https://www.reportlinker.com/p05974341/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Link:
Asia Pacific Stepper Motor Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Technology, and End user, and Country -...

TipRanks

President Trumps announcement that he has tested positive for the corona virus has grabbed headlines, but the dog that didnt bark presents a more interesting point. Wall Street isnt so worried about corona virus anymore; the perception is, that the virus will fade away or a vaccine will be developed, but in either case, the economy will improve.According to an RBC survey of portfolio managers, however, the coming November election presents a clear risk to the markets. A large majority of investors surveyed, 76%, worry that the election will be contested, resulting in weeks possibly months on uncertainty. And uncertainty is bad for the markets.Recent events, and some not-to-distant history, bear them out. For the history, we must only look back to 2000, when it took until December 12, and an appeal to the Supreme Court, to decide the results of the Florida recount. The S&P 500 slipped 5% during those weeks and that was uncertainty caused by one state, recounting a limited number of votes. The point here is not that this election will be fraudulent or illegitimate. Rather, like Caesars wife, the election should be above the perception of impropriety and this year, that bar may be too high. And then the challenges will begin. In the RBC survey, 83% of portfolio managers believed that such challenges, contesting the election results (from either direction) would be a net negative for the stock market. And only a small minority, 14%, believe that the final results will be known when the polls close on Election Day, November 3.And this is what brings us to dividend stocks today. When investors get nervous, they go looking for a way to protect their portfolios and dividends, making the promise of a steady income stream, may be just the answer skittish shareholders are looking for.Analysts from research firm Compass Point agree. They have picked three stocks whose dividends are yielding 7% or more. Weve pulled up the TipRanks data to find out what else makes these compelling buys in turbulent times.Saratoga Investment Corporation (SAR)Well start with Saratoga Investment Corporation, a mid-market investment management company that specializes in debt, appreciation, and equity investments. Saratoga has over $480 million in assets under management, and its portfolio includes home security, industry, software, and waste disposal. The variety, and the stocks chosen, are designed to give the company a resilient income stream.That doesnt mean that Saratoga has been able to dodge the corona bullet. The company saw revenues turn negative in Q2, and has seen EPS slip from 61 cents in the first quarter to 51 cents in the second. As a result, Saratoga announced that it was deferring its fiscal Q4 dividend, as a cash-saving measure during the pandemic crisis.Saratoga, in July, declared its fiscal Q1 dividend for 40 cents per common share and paid it out in August. There are grounds for confidence. The company has $9 million in committed, but undrawn, lending available, along with $155 million in available credit facilities, a new $43.1 million baby bond issue, and $282 million equity all set against just $60 million in long-term debt.As for the restored dividend, while down 28% from the companys last dividend payment, the new distribution reflects Saratogas liquidity position. The current payment annualizes to $1.60, and gives a yield of 9.2%, or more than 4.5x the average yield found among S&P-listed companies.Covering the stock for Compass Point, analyst Casey Alexander writes of the new dividend, [With] the dividend now officially reset at $0.40 per quarter, it's time to make lemonade from the lemons investors were handed In our view, while we may not be done with credit issues, SAR has set the dividend at a level that allows the BDC to return to the pattern of QoQ dividend increases as the current earnings power of the BDC well exceeds the level of the new dividend.Taking everything into account, Alexander rates SAR stock a Buy, and gives it a $19.75 price target implying an upside of 16% for the coming year. (To watch Alexanders track record, click here)Overall, Saratoga gets a unanimous Strong Buy rating from the analyst consensus, based on 3 recent positive reviews. The shares are selling for $17.02 and have an average price target of $22.58, slightly more bullish than Alexanders and suggesting a one-year upside of ~33%. (See SAR stock analysis on TipRanks)Solar Capital, Ltd. (SLRC)The next stock on our list, Solar Capital, is an investor in senior secured loans and subordinated debt, with an investment portfolio of middle-market companies. The company puts capital into investment-grade loan instruments, making additional financing available to its customer base. Solar Capital has a portfolio worth $1.4 billion invested in 183 companies across 80 business sectors.Solar Capital has been able to keep earnings positive during the corona half, despite a sharp fall in the bottom line for Q1 and Q2. In a bright spot, revenues, which turned negative in Q1, were back to positive in Q2, and projections for Q3 earnings show that the fall-off is either slowing or stopping we will find out which in the Q3 report on November 5.Through all of this uncertainty, Solar Capital has kept up its stable dividend. The company has a 7-year history of reliable dividend payments, and the current quarterly dividend of 41 cents has been paid out consistently for the last 11 quarters. At an annualized payment of $1.64, the dividend currently yields 10.5%. In a time of near-zero official interest rate policy, this gives SLRC an enviable return.Compass Point's Casey Alexander, who also covers SAR, points out that SLRCs dividend is the main attraction for investors and that management has cultivated it for just that purpose. Management stated their intention to continue to pay the $0.41 per share dividend because they believe there is visibility to dividend coverage as they begin to originate new assets at higher spreads. This is the environment that SLRC has been waiting for, and has been the principal reason for maintaining an under-leveraged posture for the last several years, Alexander noted.With dividend coverage visible ahead, Alexander gives SLRC a Buy rating. His price target, at $17.75, indicates confidence in a 12% upside potential.This is another stock with a unanimous Strong Buy consensus rating. SLRC is sitting pretty with 5 positive reviews on record. The average price target is $18.20, representing a ~15% upside from the current share price of $15.86. (See SLRC stock analysis on TipRanks)First Hawaiian (FHB)Our last stock today, First Hawaiian, is the holding company owning the First Hawaiian Bank. First Hawaiian offers the usual array of banking services to retail and commercial customers, with 53 branches throughout the Hawaiian Islands along with three others in Guam and two on Saipan. Banking services include loans, deposit accounts, credit and debit cards, mortgages, insurance, and retirement plans.The recently ended second-quarter showed some mixed results. Top line revenues showed a sequential slip, from $164 million to $152 million, but that was mild compared to the 46% drop in earnings. EPS for Q2 came in at 16 cents, on $20 million in net income. Bright spots for the quarter were total loans, which grew 3% to $383 million, and deposit balances, which increased 13% sequentially to reach $2.3 billion. The banks total assets at the end of 2Q20 were $23 billion, up 10% from the end of the first quarter.That is the background behind managements July dividend declaration. The company Board approved a 26-cent regular quarterly dividend, which was paid out in early September. At $1.04 annualized, this dividend yields 7.2%, putting it well above the average yield and far higher than the current yield on Treasury bonds. FHB has a 4-year history of reliable dividend payments, and the current declaration marks the seventh quarter in a row at the current level.Compass Point analyst Laurie Havener Hunsicker believes a macro look at FHB justifies a bullish stance. FHB was a clear outperformer on credit during the last crisis. While past results do not dictate future performance, we are impressed with the FHB management team and their credit culture; further, we believe that FHB is well-postured to again outperform on credit during the COVID-19 crisis, the analyst noted.In line with her comments, Hunsicker rates FHB a Buy and sets a $21 price target that suggests room for a robust share appreciation of 46% over the next year. (To watch Hunsickers track record, click here)However, Wall Street is unsure on FHB, and the analysts are evenly divided, with recent reviews coming in at 1 Buy, 1 Hold, and 1 Sell for an analyst consensus rating of Hold. FHB shares are selling for $14.42 and have an average price target of $16.67, making the upside potential 15%. (See First Hawaiians stock analysis at TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more from the original source:
Whole Exome Sequencing - Global Market Trajectory & Analytics to 2027 with Short-Term COVID-19 Impact Analysis 2020-2021 - ResearchAndMarkets.com...

NEW YORK, Sept. 30, 2020 /PRNewswire/ --The North America neurological biomarkers market is expected to reach US$ 2,618.68 Mn in 2027 from US$ 7,056.76 Mn in 2019. The market is estimated to grow with a CAGR of 13.4% from 2020-2027.

Read the full report: https://www.reportlinker.com/p05974400/?utm_source=PRN

Factors such as growing prevalence of neurological disorders and increasing focus toward research in neurological biomarker are expected to fuel the growth of the market.However, the limitation of neurological biomarkers is a major factor hindering the market growth.

In addition, increasing awareness toward benefits of early diagnosis is expected to provide growth opportunities to the market players for developing new biomarkers whereas, the inclination toward personalized/precision medicine is expected to be a prevalent trend in the market.Biomarkers are the molecules that indicate about the presence of a disease.The biomarkers of the neurological diseases were not that accessible in earlier days, however the advancements in the technology have enabled to track the health condition of the brain by measuring the biomarkers.

This helps in the earlier detection of a disease, less invasive diagnostics and enables faster drug development and is expected to be the effective treatment.Rapid developments in healthcare and drug discovery sector are leading to the introduction of new therapeutic solutions for the treatment of neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage the research activities and find a remedy for neurological disease treatment.A biomarker is an indicator of normal biological processes, pathogenic processes, or evaluating a therapeutic intervention. Thus, the discovery of biomarker is an active research area, where a few biomarkers have been sufficiently studied and validated for its use in clinical practice and clinical trials.The National Institute of Neurological Disorders and Stroke (NINDS) biomarker program is focused on enhancing the quality and efficiency of neurotherapeutic clinical research and supports the biomarker validation.The program promotes rigorous biomarker identification and validation by providing funds for the research activities.

Similarly, Parkinson's disease Biomarkers Program (PDBP) was initiated to support new and existing research promoting the discovery of biomarker for Parkinson's disease. Thus, increasing number of research studies conducted in the North American region focusing toward advancements in neurological biomarker are expected to augment the growth of the market over the forecast period.

Research institutes, pharmaceutical, and biotech companies are engaged in collaborative work to address the COVID-19 outbreak.This has eventually shifted their focus from development of new neurological biomarkers to vaccine development for COVID-19.

Moreover, diversion of resources from neurological biomarkers development to coronavirus treatment is likely to hamper overall productivity of the drug development during the forecast period. Furthermore, supplies for biotechnology procedures and procurement are also badly affected by the outbreak of COVID-19 in North America.In 2019, the genomic biomarkers segment held the largest share of the market and is expected to grow at the fastest CAGR during the forecast period.This segment is likely to witness a lucrative growth owing to increasing awareness among consumers regarding benefits of genetic medicines as well as technological advancements in the field of neurological biomarkers.

In addition, the trend shift towards adoption of gene counseling and genetic analysis for diagnostic purposes is also likely to augment the growth of the segment. The genetic biomarkers are significant modalities that directs towards a more personalized approach of predispositions and medical analysis.Some of the significant secondary sources for neurological biomarkers market included in the report are the World Health Organization (WHO), Food and Drug Administration (FDA),National Institute of Neurological Disorders and Stroke (NINDS),Centers for Disease Control and Prevention (CDC),and others.

Read the full report: https://www.reportlinker.com/p05974400/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

View original post here:
The North America neurological biomarkers market is expected to reach US$ 2,618.68 Mn in 2027 from US$ 7,056.76 Mn in 2019 - PRNewswire

Some of the prominent players operating in the precision medicine software market include 2bPrecise, Syapse, Inc., IBM Corporation

Precision medicine is a prototype in healthcare which provides the customization of healthcare with medical decisions, practices, treatments, and products for patients in person. It states about right therapeutic approach for the right patient at the right time. The use of precision medicine is to identify which treatment approach is effective for patients on the basis of genetic, environment, and lifestyle factors. Precision medicine software allows the healthcare professionals (HCPs) to provide personalized treatment plans to patients based on their genetic content. It gives a wide range of applications in both the clinical and diagnostic areas and it combines genetic and clinical data to cater targeted patient care, which is increasing the demand of precision medicine software market.

Request a [emailprotected] https://www.absolutemarketsinsights.com/request_sample.php?id=349

The global precision medicine software market is experiencing lucrative growth owing to the increase in the number of patients suffering from chronic diseases such as cancer, heart diseases, and diabetes. For instance, as per the data presented by International Agency for Research on Cancer (IARC), in 2018, the cancer burden was 18.1 million new cases and 9.6 million deaths across the world. One in five men and one in six women around the globe develop cancer during their lifetime, and one in eight men and one in 11 women die from the disease.

Koninklijke Philips N.V. (Philips Healthcare), a multinational electronics company focusing on healthcare, offers precision medicine platform, namely, IntelliSpace. It enables end-to-end oncology care or cancer management. The platform unifies and streamlines oncology care throughout the patient journey from molecular diagnostics to therapy recommendations. IntelliSpace, a precision medicine oncology solution integrates information over different clinical domains such as pathology, electronic health record (EHR) systems, radiology, and genomics. It consolidates all key patient and medical data in one location to represent a clear, comprehensible view of patient status in its disease and enable data driven clinical decision support, which in turn is propelling the precision medicine software market.

Enquiry Before [emailprotected] https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=349

Precision medicine with the integration of artificial intelligence (AI) will go to the next level with more accuracy and prediction of outcome for patients. Its major benefit for precision medicine is that it predicts outcomes as well as enables healthcare professionals to predict patients probability of having diseases in the future, thus driving the demand of precision medicine software market. Oracle, an American multinational computer technology corporation offers precision medicine software that enables researchers, clinicians, and molecular pathologists to work together. The software addresses data aggregation, normalization and workflow issues, knowledge exchange which restricts timely creation of patient molecular profiles and it also enables spectrum testing from gene panels through whole genome sequencing, and integration with electronic health record systems for seamless clinical workflow.

The detailed research study provides qualitative and quantitative analysis of the global precision medicine software market. The precision medicine software market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Request for [emailprotected] https://www.absolutemarketsinsights.com/request_for_customization.php?id=349

Key Findings of the Report:

Global Precision Medicine Software Market

Get Full Information of this premium [emailprotected] https://www.absolutemarketsinsights.com/reports/Precision-Medicine-Software-Market-2019-2027-349

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Company: Absolute Markets Insights

Email id: [emailprotected]

Phone: +91-740-024-2424

Contact Name: Shreyas Tanna

The Work Lab,

Model Colony, Shivajinagar, Pune, MH, 411016

Website: https://www.absolutemarketsinsights.com/

Continue reading here:
Astonishing growth in Precision Medicine Software Market is expected to grow at CAGR 12.3% from 2019 to 2027 - Crypto Daily

Americans encounter some form of artificial intelligence and machine learning technologies in nearly every aspect of daily life: We accept Netflixs recommendations on what movie we should stream next, enjoy Spotifys curated playlists and take a detour when Waze tells us we can shave eight minutes off of our commute.

And it turns out that were fairly comfortable with this new normal: A survey released last year by Innovative Technology Solutions found that, on a scale of 1 to 10, Americans give their GPS systems an 8.1 trust and satisfaction score, followed closely by a 7.5 for TV and movie streaming services.

But when it comes to higher stakes, were not so trusting. When asked about whether they trust an AI doctor diagnosing or treating a medical issue, respondents scored it just a 5.4.

CMS Doubles Down on CAHPS and Raises the Bar on Member Experience

A new CMS final rule will double the impact of CAHPS and member experience on a Medicare plans overall Star Rating. Learn more and discover how to exceed member expectations and improve Star Ratings in this new whitepaper.

Overall skepticism about medical AI and ML is nothing new. In 2012, we were told that IBMs AI-powered Watson was being trained to recommend treatments for cancer patients. There were claims that the advanced technology could make medicine personalized and tailored to millions of people living with cancer. But in 2018, reports surfaced that indicated the research and technology had fallen short of expectations, leaving users to speculate the accuracy of Watsons predictive analytics.

RELATED:Investors poured $4B into healthcare AI startups in 2019

Patients have been reluctant to trust medical AI and ML out of fear that the technology would not offer a unique or personalized recommendation based on individual needs. A piece in Harvard Business Review in 2019 referenced a survey in which 200 business students were asked to take a free health assessment to perform a diagnosis40% of students signed up for the assessment when told their doctor would perform the diagnosis, while only 26% signed up when told a computer would perform the diagnosis.

These concerns are not without basis. Many of the AI and ML approaches that are being used in healthcare todaydue to simplicity and ease of implementationstrive for performance at the population-level by fitting to the characteristics most common among patients. They look to do well in the general case, failing to serve large groups of patients and individuals with unique health needs. However, this limitation of how AI and ML is being applied is not a limitation of the technology.

If anything, what makes AI and ML exceptionalif done rightis its ability to process huge sets of data comprising a diversity of patients, providers, diseases and outcomes and model the fine-grained trends that could potentially have a lasting impact on a patients diagnosis or treatment options. This ability to use data in the large for representative populations and to obtain inferences in the small for individual-level decision support is the promise of AI and ML. The whole process might sound impersonal or cookie-cutter, but the reality is that the advancements in precision medicine and delivery will make care decisions more data-driven and thus more exact.

Consider a patient choosing a specialist. Its anything but data-driven: Theyll search for a provider in-network or maybe one that is conveniently located, without understanding potential health outcomes as a result of their choice. The issue is that patients lack the proper data and information they need to make these informed choices.

RELATED:The unexpected ways AI is impacting the delivery of care, including for COVID-19

Thats where machine intelligence comes into playan AI/ML model that is able to accurately predict the right treatment, at the right time, by the right provider for a patient, which could drastically help reduce the rate of hospitalizations and emergency room visits.

As an example, research published last month in AJMC looked at claims data from 2 million Medicare beneficiaries between 2017 and 2019 to evaluate the utility of ML in the management of severe respiratory infections in community and post-acute settings. The researchers found that machine intelligence for precision navigation could be used to mitigate infection rates in the post-acute care setting.

Specifically, at-risk individuals who received care at skilled nursing facilities (SNFs) that the technology predicted would be the best choice for them had a relative reduction of 37% for emergent care and 36% for inpatient hospitalizations due to respiratory infections compared to those who received care at non-recommended SNFs.

This advanced technology has the ability to comb through and analyze an individuals treatment needs and medical history so that the most accurate recommendations can be made based on that individuals personalized needs and the doctors or facilities available to them. In turn, matching a patient to the optimal provider has the ability to drastically improve health outcomes while also lowering the cost of care.

We now have the technology where we can use machine intelligence to optimize some of the most important decisions in healthcare. The data show results we can trust.

Zeeshan Syed is the CEO and Zahoor Elahi is the COO of Health at Scale.

Read more from the original source:
Industry VoicesAI doesn't have to replace doctors to produce better health outcomes - FierceHealthcare

DUBLIN--(BUSINESS WIRE)--The "Global Mice Model Market by Mice Type (Inbred, Knockout), Technology (CRISPR, TALEN, ZFN), Application (Oncology, Diabetes, Immunology), Service (Breeding, Cryopreservation, Genetic Testing), Care Products (Cages, Bedding, Feed), and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global mice model market size is projected to reach USD 1.9 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.4% during the forecast period.

The growth of this market is driven mainly by ongoing innovations in mice models, growing demand for personalized medicine, continuous support in the form of grants and investments, growth in the number of pharmaceutical R&D activities, and increasing focus of associations on the development of embryonic stem cells as well as knockout and mutant mice. Moreover, the popularity of humanized mice models and emerging technologies such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) will present lucrative opportunities for the market in the coming years.

By mice type, the genetically engineered mice accounted for the fastest-growing segment of the mice model market

Genetically engineered mice segment is anticipated to be the fastest-growing due to the widespread use of these mice in diverse research areas, the emerging CRISPR technology, increasing focus on personalized medicine with the continuous introduction of new models

By service, the breeding segment accounted for the largest share of the mice model market

The breeding segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing demand for mice models for drug discovery and development and the subsequent increase in the demand for personalized medicines.

Oncology segment expected to grow at the fastest growth rate during the forecast period

Based on application, the mice model market has been segmented into oncology studies, immunology and inflammation studies, endocrine metabolic studies, cardiovascular studies, central nervous system studies (CNS), genetic studies, infectious disease studies, and other disease studies. The endocrine disease studies segment is further segmented into diabetes and other endocrine metabolic disease. The oncology segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing number of patients who have cancer and the subsequent increase in the demand for cancer therapies.

By technology type, CRISPR/Cas9 accounted for the largest share of the mice model market

CRISPR is the most widely used technology in the mice model market and contributed to the largest share of the mice model market in 2020. Ease of design, high efficiency, and relatively lower cost have increased the demand for CRISPR-customized mice models.

By mice care product, cages segment accounted for the largest share of the mice model market

Based on mice care products, the mice model market has been segmented into cages, feed, bedding, and other products (gnotobiotic equipment, water systems, and accessories). The cages segment accounted for the largest share of the mice model market. This can be attributed to the availability of a wide range of cages designed for specific research needs and the higher cost of cages compared to other care products.

Asia Pacific: The fastest-growing region in the mice model market

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their drug discovery R&D operations and manufacturing to the region. A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.

North America: The largest share of the drug discovery services market

North America, which includes the US and Canada, accounted for the largest share of the mice model market. The large share of the North America region can be attributed to the presence of major players operating in the mice model market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/17ab4p

Go here to see the original:
$1.9 Billion Mice Model Market by Mice Type, Technology, Application, Service, Care Products - Global Forecast to 2025 - ResearchAndMarkets.com -...